Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Trevena, Forest sign collaborative agreement to develop TRV027 for treatment of ADHF

Trevena, Inc., a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptor biased ligands, and Forest Laboratories Holding Limited, a subsidiary of Forest Laboratories Inc., an international pharmaceutical company, announced today that they have entered into a collaborative licensing option agreement for the development of TRV027, an AT1R biased-ligand that recently completed Phase 2a clinical trials.

9 May 2013

Isis begins clinical study of ISIS-STAT3 in patients with metastatic liver cancer

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1b/2a clinical study of ISIS-STAT3Rx in patients with advanced metastatic hepatocellular carcinoma (HCC).

7 May 2013

Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73

Anavex Life Sciences Corp. ("Anavex") (OTCQB: AVXL) today announced that it has been invited to submit a full grant application to the Alzheimer's Drug Discovery Foundation ("ADDF") for a Phase 2a trial of ANAVEX 2-73.

7 May 2013

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body.

7 May 2013

Researchers explore biological processes of stem cell division

The human body contains trillions of cells, all derived from a single cell, or zygote, made by the fusion of an egg and a sperm. That single cell contains all the genetic information needed to develop into a human, and passes identical copies of that information to each new cell as it divides into the many diverse types of cells that make up a complex organism like a human being.

6 May 2013

Pharmapendium adds new module to benefit researchers and toxicologists

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announces that PharmaPendium, the leading source of preclinical, clinical and post-market data, has added a new module to its content base, the Metabolizing Enzymes and Transporters Module.

6 May 2013

Researchers create "designer" tracer for earlier diagnosis and better treatments of Alzheimer's

One of the biggest challenges with Alzheimer's disease (AD) is that by the time physicians can detect behavioral changes, the disease has already begun its irreversibly destructive course.

26 Apr 2013

Thermo Fisher Scientific brings several innovations in bioprocessing technologies and systems

Thermo Fisher Scientific Inc., the world leader in serving science, today debuted several innovations in bioprocessing technologies and systems that address the evolving requirements of drug discovery and production for global biopharmaceutical and pharmaceutical manufacturers.

From Thermo Fisher Scientific Inc. 26 Apr 2013

Rexceptor receives exclusive license for novel treatment of Alzheimer's disease

Case Western Reserve's Technology Transfer Office has granted an exclusive license of a novel Alzheimer's Disease (AD) treatment strategy to spinoff company ReXceptor Inc., which plans to initiate early-stage human clinical trials of the medication within the next few months.

26 Apr 2013

Advaita selected to participate in Michigan I-Corps program starting May 2013

Advaita, a Plymouth, MI biotechnology startup company spun out from Wayne State University, is one of 25 companies selected to participate in the new Michigan I-Corps program starting May 2013.

24 Apr 2013

Promising development for women with triple-negative breast cancer

Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen's secondary activities so that it might work on more aggressive breast cancer.

24 Apr 2013

Aurigene and Endo’s collaborative efforts yield novel drug candidates

Aurigene and Endo entered into collaboration in 2009, for multiple integrated drug discovery programs in the areas of Inflammation and Oncology.

22 Apr 2013

BGI's second International Conference on Genomics in the Americas to be held in September

BGI, the world's largest genomics organization, will hold its second International Conference on Genomics in the Americas (ICG Americas 2013) on September 12-13, 2013 in Sacramento, CA.

17 Apr 2013

Preclinical data on anti-cancer activity of BI-505 published online in Cancer Cell

BioInvent International AB, a biotech company developing novel antibody therapeutics for treatment of cancer, today announced that the April 15, 2013 online issue of the highly prestigious cancer research journal Cancer Cell features a data publication demonstrating potent anti-cancer activity of BI-505 in multiple preclinical myeloma tumor models.

17 Apr 2013

TSRI scientists shed light on major toxic mechanisms of Alzheimer's disease

Scientists at The Scripps Research Institute have shed light on one of the major toxic mechanisms of Alzheimer's disease. The discoveries could lead to a much better understanding of the Alzheimer's process and how to prevent it.

11 Apr 2013

Cellectis CanCELL cell lines enable drug positioning in cancer pathways

CanCELL cell lines are featuring gene knock-outs of the major cancer relevant oncogenes and tumor suppressor genes. This new product line answers identified market needs in oncology research and drug discovery.

11 Apr 2013

Scientists demonstrate feasibility of using already-approved drugs against pathogens

In the most extensive screen of its kind, Texas Biomed scientists in San Antonio have demonstrated the feasibility of repurposing already-approved drugs for use against highly pathogenic bacteria and viruses.

11 Apr 2013

GGA Software Services, Pfizer to present Indigo ELN at 2013 Bio-IT World Conference and Expo

GGA Software Services LLC, a leading provider of outsourced scientific informatics and software services to the life sciences industry, announced today that GGA and Pfizer will present Indigo ELN, the industry's leading open-source chemistry electronic laboratory notebook, at the 2013 Bio-IT World Conference and Expo in Boston, Massachusetts, on Wednesday, April 10, at 12:00 PM.

From Pfizer, Inc. 10 Apr 2013

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

10 Apr 2013

Bayer HealthCare and German Cancer Research Center to extend strategic alliance in search of novel cancer therapeutics

Bayer HealthCare (Bayer) and the German Cancer Research Center (DKFZ) will extend their successful strategic research alliance in search of novel cancer therapeutics by focusing their activities also on the field of immunotherapy. Immunotherapies are a promising approach to treat cancer with the aim to selectively reactivate the body's own immune system so that it attacks tumor cells.

10 Apr 2013

Drug Discovery News and Research

Further Reading

Trevena, Forest sign collaborative agreement to develop TRV027 for treatment of ADHF

Isis begins clinical study of ISIS-STAT3 in patients with metastatic liver cancer

Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Researchers explore biological processes of stem cell division

Pharmapendium adds new module to benefit researchers and toxicologists

Researchers create "designer" tracer for earlier diagnosis and better treatments of Alzheimer's

Thermo Fisher Scientific brings several innovations in bioprocessing technologies and systems

Rexceptor receives exclusive license for novel treatment of Alzheimer's disease

Advaita selected to participate in Michigan I-Corps program starting May 2013

Promising development for women with triple-negative breast cancer

Aurigene and Endo’s collaborative efforts yield novel drug candidates

BGI's second International Conference on Genomics in the Americas to be held in September

Preclinical data on anti-cancer activity of BI-505 published online in Cancer Cell

TSRI scientists shed light on major toxic mechanisms of Alzheimer's disease

Cellectis CanCELL cell lines enable drug positioning in cancer pathways

Scientists demonstrate feasibility of using already-approved drugs against pathogens

GGA Software Services, Pfizer to present Indigo ELN at 2013 Bio-IT World Conference and Expo

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Bayer HealthCare and German Cancer Research Center to extend strategic alliance in search of novel cancer therapeutics

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News